Currently in veterinary oncology all chemotherapeutic agents are used on an off-label basis, however, this is about to change. The conditionally approved Paccal Vet® is a member of the taxane family and in human oncology, taxanes have been shown to have activity against many cancer histologies including mammary cancer, head and neck squamous cell carcinoma, ovarian cancer, lung cancer, Kaposi sarcoma, gastric cancer, prostate cancer, soft tissue sarcoma, and bladder cancer.
Veterinary hospital doctors and support staff are invited to field a team(s) and bring their adoring public to cheer them on as they compete in interactive, intellectual and physical games in the ACF Veterinary Challenge™.
With an accuracy rating of 98 percent, specially-trained dogs were able to smell volatile organic compounds (VOCs) released into urine by prostate tumors, setting the stage for a potentially new means of early prostate cancer detection, according to a new study at the 109thAnnual Scientific Meeting of the American Urological Association (AUA). The study will be presented to the media during a special press conference on Sunday, May 18 at 1:00 p.m. at the Orange County Convention Center, Orlando, FL.
You probably learned in school that cancer is caused by the mutation of cells that grow out of control causing tumors.
This view was first suggested in 1928 and has held pretty fast in the minds of the medical and scientific communities for some 85 years, despite the fact that this mutation theory has been proven true for less than 10 percent of cancers.
Sophie is an 11 year-old, female spayed Tibetan terrier. She presented to the Veterinary Cancer Center in May of 2012 after a one-week history of vomiting, diarrhea, hyporexia and episodes of increased respiratory effort. An abdominal ultrasound prior to presentation revealed multiple hepatic masses, a duodenal mass and a mass adjacent to the left adrenal gland. The findings were thought to be most consistent with a metastatic, infiltrative neoplastic process (carcinoma was the top differential).
We are well into The VCC’s second year of being open in our new building! It has been a very exciting ride, with lots of amazing advances and many opportunities still being pursued.
This time of year always brings back memories of the construction phase of the hospital, when we had to ask ourselves a lot of important questions. Some of the more interesting ones where: What is the local impact of our veterinary center on the community? How long would it take from planning to operation to launch our new hospital? What do we think the future holds for veterinary oncology in general?
A 13-year old female spayed mixed breed presented to the VCC for consultation regarding an incompletely excised oral malignant melanoma. The mass was removed in early June from the left mandibular gingiva at the level of the canine tooth and had a reported MI of 38 per 10 hpf. At her initial consultation in late July, a 1 cm darkly pigmented mass was found at the area of the previous surgery and was confirmed to be disease recurrence via cytology. Thoracic radiographs were negative for pulmonary metastasis. The owner elected not to pursue further surgery, so we recommended the melanoma
Stanford researchers are on track to begin human trials of a potentially potent new weapon against cancer, and would-be participants are flooding in following the Post’s initial report on the discovery.
The progress comes just two months after the groundbreaking study by Dr Irv Weissman, who developed an antibody that breaks down a cancer's defense mechanisms in the body. Read More...
Scientists think they have discovered why cancer spreads from one part of the body to another, and say it will be "relatively easy" to stop the process. Experiments carried out by a team at University College London uncovered what causes the disease to migrate.